YQYushen Qian

Yushen Qian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yushen Qian has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Ann K. Folkins

    Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA

    1 shared publication
  • Chika Nwachukwu

    Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA

    1 shared publication
  • Daria M. Tanska

    Authors' Affiliations: Departments of 1Radiation Oncology, 2Pharmacology, and 3Surgery, University of Michigan Medical School; 4Biostatistics Unit, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; and 5AstraZeneca R&D Boston, Waltham, Massachusetts

    1 shared publication
  • Deborah Morosini

    Authors' Affiliations: Departments of 1Radiation Oncology, 2Pharmacology, and 3Surgery, University of Michigan Medical School; 4Biostatistics Unit, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan; and 5AstraZeneca R&D Boston, Waltham, Massachusetts

    1 shared publication
  • Diane M. Simeone

    Moores Cancer Center, UC San Diego Health, San Diego, USA

    1 shared publication
  • Elizabeth A. Kidd

    Department of Radiation Oncology, Stanford University, Stanford, CA

    1 shared publication

Latest Publications

  • Extent of lymphovascular space invasion may predict lymph node metastasis in uterine serous carcinoma

    by Yushen Qian, Erqi L. Pollom, Chika Nwachukwu, Kira Seiger, Rie von Eyben, Ann K. Folkins, Elizabeth A. Kidd


  • Open Access

    Assessment of Chk1 Phosphorylation as a Pharmacodynamic Biomarker of Chk1 Inhibition

    by Leslie A. Parsels, Yushen Qian, Daria M. Tanska, Marisa Gross, Lili Zhao, Maria C. Hassan, Sankari Arumugarajah, Joshua D. Parsels, Linda Hylander-Gans, Diane M. Simeone, et al.

    Purpose: Chk1 inhibitors, such as AZD7762, are in clinical development in combination with cytotoxic agents for the treatment of solid tumors, including pancreatic cancers. To maximize the likelihood of their clinical success, it is essential to optimize drug scheduling as well as pharmacodynamic biomarkers in preclinical models. Experimental Design: We tested multiple schedules of administration of gemcitabine and AZD7762 on the survival of pancreatic cancer cells. Potential pharmacodynamic biomarkers including pChk1, pChk2, pHistone H3, and caspase-3 were evaluated in vitro, followed by assessment of promising candidate biomarkers in vivo. We then went on to determine the contributions of PP2A and DNA damage to the mechanism(s) of induction of the identified biomarker, pS345 Chk1. Results: AZD7762 given during and after or after gemcitabine administration produced maximum chemosensitization. In vivo, AZD7762 significantly inhibited the growth of pancreatic tumor xenografts in response to gemcitabine. Of the biomarkers assessed, pS345 Chk1 was most consistently increased in response to gemcitabine and AZD7762 in tumors and normal tissues (hair follicles). pS345 Chk1 induction in response to gemcitabine and AZD7762 occurred in the presence of PP2A inhibition and in association with elevated γH2AX, suggesting that DNA damage is an underlying mechanism. Conclusions: AZD7762 sensitizes pancreatic cancer cells and tumors to gemcitabine in association with induction of pS345 Chk1. Together these data support the clinical investigation of AZD7762 with gemcitabine in pancreatic cancer under a dosing schedule in which gemcitabine is administered concurrent with or before AZD7762 and in conjunction with skin biopsies to measure pS345 Chk1. Clin Cancer Res; 17(11); 3706–15. ©2011 AACR.